LKYSF - Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy

VANCOUVER, BC, July 12, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that Health Canada has cleared the MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This study is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the  ...